We determined type-specific antibodies to herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) by an indirect enzyme-linked immunosorbent assay, using as antigens HSV-1 glycoprotein gC-1 and a HSV-2-specific polypeptide purified on affinity columns of monoclonal antibodies. All sera were initially screened for HSV antibodies by the enzyme-linked immunosorbent assay with a pool of Triton X-100-extracted antigens of HSV-1-and HSV-2-infected HEp-2 cells. The titer of HSV antibodies was predicted from a linear regression curve based on the absorbance of the initial 1:50 serum dilution. The sensitivity and specificity of the screening assay and of the assay for type-specific antibodies were established.
cific HSV-1 and HSV-2 antibodies has been difficult because of the strong cross-reactivity between the two viruses (11, 21) . Several techniques have been applied to the problem of differentiating human sera reactive with HSV-1, HSV-2, or both. These include micro-neutralization tests (13, 14, 20) , fluorescent-antibody tests (25) , antibody-complement cytolysis (24) , hemagglutination-inhibition assays (2, 3, 21, 22) , enzyme-linked immunosorbent assays (ELISA) (26) , and radioimmunoassay (6, 7, 9, 15) .
The optimal way would be to test the reactivity of sera with purified type-specific antigens. This approach became technically possible with the development of monoclonal antibodies to several HSV-1 and HSV-2 proteins (17, 18) . Thus, monoclonal antibodies have been used to prepare immunoaffinity columns for the purification of HSV glycoproteins gD (5) and HSV-1 glycoprotein gC (1) . In addition, monoclonal antibody H379, which has been found to react type specifically with HSV isolates (17, 18) , has been used to purify a HSV-2-specific polypeptide (L. Pereira and D. Dondero, manuscript in preparation).
In this report, we describe two types of enzyme immunoassays. The first is for the detection and titration of total antibodies to HSV-1 and HSV-2 with antigens prepared by extracting infected cells with Triton X-100. The second assay is for HSV type-specific antibody differentiation with the immunoaffinity-purified HSV-1-specific glycoprotein gC and a type-specific HSV-2 polypeptide.
MATERIALS AND METHODS Patient population. Sera were obtained from individuals with clinically manifest and culturally proven primary or recurrent infections with HSV-1 or HSV-2 or both. All viral isolates were typed as HSV-1 or HSV-2 by direct immunofluorescence (12) . HSV infections were classified as primary infections if the individual had no preexisting neutralizing antibody to HSV-1 or HSV-2 and seroconversion was documented. For certain studies, we used sera which had already been tested by neutralization assays for other purposes and a collection of sera from children 2 to 12 years of age.
Crude antigen preparations. For the routine screening of sera for HSV antibodies, antigens were prepared from HEp-2 cells infected with HSV-1 (F strain) and HSV-2 (G strain). After 4+ cytopathic effect (80 to 90%6 of the cells were rounded) was observed (24 to 48 h), the cells were harvested, sonicated in pH 8.6 Trisglycine buffer containing 2% Triton X-100 (27) , clarified by centrifugation, and stored at -70°C. Control antigens of uninfected HEp-2 cells were prepared by the same protocol.
Purification of HSV proteins. The properties of monoclonal antibodies HCI and H379 used to prepare immunoaffinity columns were reported previously (17, 18) . The procedures for the preparation of the affinity columns and elution of the proteins were as previously described (1, 8) .
ELISA. ELISA (28) ELISA was found to have increased sensitivity, at a starting serum dilution of 1:50, compared with the microneutralization test, at a starting dilution of 1:10. A total of 75 sera were positive for HSV antibodies by both tests, and 62 were negative by both tests. None was positive by the microneutralization assay and negative by ELISA, but 21 were negative by the microneutralization assay and positive by ELISA. It is unlikely that the positive results of these 21 sera that were negative by microneutralization represent false-positive reactions. Nine of these specimens were acute sera from individuals with primary genital HSV infections, five were acute sera from patients with herpes encephalitis, and six were acute sera from neonates with HSV. The remaining ELISA-positive neutralization-negative serum was from a patient who, although HSV culture negative from a suspect genital lesion, had later sera that were positive for HSV antibodies by both tests. Five of these sera had previously been found to be HSV-antibody positive by indirect hemagglutination tests (21) . Six of the sera were also tested by antibody-dependent cellular cytotoxicity (23) and found to be positive.
The screening assay was found to have a high degree of reproducibility. Based on the results of 11 assays, the mean specific absorbance of the and actual titers were high-positive serum was found to be 1.92 + 0.6, that of the medium-positive serum was 1.03 + 0.07, and that of the negative serum was 0.06 + 0.03. The coefficient of variation for these control sera ranged from 3 to 6.8%.
Titer prediction from the linear regression curve was also shown to have a good accuracy index. As verified by the actual titration of 20 sera, predicted titers and actual titers were noted to be highly correlated (r = 0.974; Table 2 ).
Assay for antibodies to purified HSV-1 and HSV-2 proteins. We tested the sera of 73 patients with primary, recurrent, or dual HSV infections by ELISA, using the affinity-purified HSV-1 and HSV-2 antigens (Table 3) . We found generally good agreement between the virus type(s) isolated from the patients and the serological responses to the purified antigens. The major exception was 1 of the 36 sera from patients with recurrent genital HSV-2 infections that failed to react with the HSV-2 purified protein. Five of twenty sera obtained within 2 to 3 weeks of onset from individuals with primary HSV-2 infections failed to react with either purified protein. This may be due to a delay in the production of antibodies to the purified HSV-2 protein, as suggested by the absence of detectable antibodies to either the HSV-1 or HSV-2 purified antigens in sera obtained within the first 7 to 14 days after onset from patients with primary HSV-1 or HSV-2 infections (data not shown).
When children between 2 and 12 years of age are infected by HSV, it is almost always HSV-1 (14) . To ascertain further the specificity of the reactions with the HSV-1 and HSV-2 purified proteins, we first tested the sera of 127 children in this age group by the screening ELISA for HSV antibodies; sera positive by this assay were then tested for reactivity with the purified proteins. Thirty-seven (29%) of the sera were found to have HSV antibodies; 34 of 37 reacted only with gC-1, none reacted with only the HSV-2-specific protein, and 1 of 37 reacted with both type-specific antigens. This serum, which apparently contained dual antibodies, was absorbed with HSV-1-and HSV-2-infected HEp-2 cells and retested. Absorption confirmed the results obtained with the purified proteins. The presence of HSV antibodies, detected by the screening assay in the two sera which were negative with both purified proteins, was confirmed by antibody-dependent cellular cytotoxicity (23) .
A comparison of the determination in 42 sera of type-specific antibodies by ELISA, using the purified HSV-1 and HSV-2 proteins, and by the microneutralization tests is given in Table 4 Using antigens prepared from Triton X-100-extracted HSV-infected cells, ELISA has been found to be a sensitive and specific test for the determination of total HSV antibodies. Extending the application of this assay by other workers (4, 5, 10, 26, 27) , we have found that, by automation and computerization, it is possible to screen and predict the titer of as many as 150 to 200 sera per day. The absorbance of the ELISA reaction with a very small volume of serum at one dilution (1:50) can be used to predict the titer of HSV antibodies. ELISA with affinity-purified HSV-1 and HSV-2 proteins has also been found to provide a sensitive and specific method for determining type-specific antibodies in sera. Our results confirm and extend the studies with radioimmunoassay using purified gC-1 recently reported by Arvin et al. (1) . Other procedures for the determination of type-specific antibodies include the absorption of sera with heterologous HSV antigen (2, 3, 6, 9, 15, 21) , the blocking of cross-reactive antigenic sites with heterologous antibody (26) , and the immunoprecipitation of HSV-specific glycoproteins with human sera followed by polyacrylamide gel electrophoresis (7) . Besides problems with incomplete absorption, these methods are not readily applicable for routine assays with large numbers of sera.
In conclusion, we have demonstrated the use of ELISA for predicting titers with one serum dilution and for determining antibodies to certain purified HSV proteins. We are currently extending these data by determining antibody titers in various immunoglobulin subclasses to other purified HSV proteins.
